ESMO Virtual Journal Club: October 2024

This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Programme

• 2 October 2024

Welcome and introduction

Toni Choueiri

Overall Survival with Adjuvant Atezolizumab after Chemotherapy in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

Sanjay Popat

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Laurence Albiges

Live Q&A and Discussion

All speakers

• 

  Toni Choueiri

  Chair

  Dana Farber Cancer Institute
• 

  Sanjay Popat

  Speaker

  Thoracic Medical Oncology,
  The Royal Marsden Hospital
  and
  The Institute of Cancer Research
  
• 

  Laurence Albiges

  Speaker

  Institut Gustave Roussy

Description

This ESMO Virtual Journal Club Webinar focused on two newly published studies, with an aim to enhance understanding and application of the latest research in the field.

This webinar aimed to discuss and evaluate notable recent publications on the topics of non-small-cell lung cancer and advanced urothelial cancer:

E. Felip, N. Altorki, C. Zhou et al. Overall Survival with Adjuvant Atezolizumab after Chemotherapy in Resected Stage II-IIIA Non-Small-Cell Lung Cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Annals of Oncology.
DOI: 10.1016/j.annonc.2023.07.001

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. New England Journal of Medicine.
DOI: 10.1056/NEJMoa2312117

Learning objectives

• To discuss and critically evaluate notable recent publications.
• To enhance the understanding and application of the latest research in the field.
• To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
• To identify and highlight any unclear aspects or unmet needs.